リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Usefulness of interleukin-18 as a diagnostic biomarker to differentiate adult-onset Still’s disease with/without macrophage activation syndrome from other secondary hemophagocytic lymphohistiocytosis in adults」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Usefulness of interleukin-18 as a diagnostic biomarker to differentiate adult-onset Still’s disease with/without macrophage activation syndrome from other secondary hemophagocytic lymphohistiocytosis in adults

志賀 俊彦 近畿大学

2023.01.20

概要

Background: Interleukin (IL)-18 is markedly elevated in systemic inflammatory diseases that cause the ‘cytokine storm’ such as adult-onset Still’s disease (AOSD) and hemophagocytic lymphohistiocytosis (HLH). The differences in IL-18 between AOSD and HLH, especially in adults, is uncertain. Macrophage activation syndrome (MAS), a form of secondary HLH, is often difficult to differentiate cases of AOSD that include MAS from other secondary HLH. In this case-control study, we investigated whether serum IL-18 levels could be a useful biomarker for the differential diagnosis of AOSD with or without MAS (AOSD group) and other secondary HLH in adults (adult HLH group).

Patients and Methods: We enrolled 46 patients diagnosed with AOSD including 9 patients with MAS and 31 patients in the adult HLH group, which excluded AOSD- associated MAS. The clinical features and laboratory data were compared between the AOSD and adult HLH groups. In addition, we subdivided the AOSD group (with or without MAS) and the adult HLH group (whether lymphoma-associated or not) and compared the four groups. A logistic regression analysis was used to identify factors with high efficacy in differentiating the two groups, followed by a receiver operating characteristic (ROC) curve analysis to evaluate the differential diagnostic ability of IL-18. We analyzed the correlation between IL-18 and various laboratory parameters in the AOSD group.

Results: Serum IL-18 levels of patients in the AOSD groups were significantly higher than those of the adult HLH groups, and were closely correlated with ferritin, soluble interleukin-2 receptor (sIL-2R), and other laboratory data. Univariate and multivariate logistic regression analyses revealed that IL-18, sIL-2R, and ‘arthralgia or arthritis’ are independent factors useful in the differential diagnosis of AOSD from adult HLH. In the differential diagnosis of both groups, the area under the curve obtained from the ROC curve of IL-18 with a cutoff value of 18,550 pg/mL was 0.91 (95% confidence interval 0.83–1.00; sensitivity 90.3%, specificity 93.5%), and the differential diagnosis ability of IL-18 was superior to that of other laboratory data.

Conclusions: IL-18 could be a useful biomarker for the differential diagnosis of AOSD and adult HLH.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Feist E, Mitrovic S, Fautrel B. Mechanisms, Biomarkers and Targets for Adult- Onset Still’s Disease. Nat Rev Rheumatol (2018) 14(10):603–18. doi: 10.1038/ s41584-018-0081-x

2. Giacomelli R, Ruscitti P, Shoenfeld Y. A Comprehensive Review on Adult Onset Still’s Disease. J Autoimmun (2018) 93:24–36. doi: 10.1016/ j.jaut.2018.07.018

3. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-Onset Still’s Disease. Autoimmun Rev (2014) 13(7):708–22. doi: 10.1016/j.autrev.2014.01.058

4. Hu Q, Shi H, Zeng T, Liu H, Su Y, Cheng X, et al. Increased Neutrophil Extracellular Traps Activate NLRP3 and Inflammatory Macrophages in Adult-Onset Still’s Disease. Arthritis Res Ther (2019) 21(1):9. doi: 10.1186/ s13075-018-1800-z

5. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary Criteria for Classification of Adult Still’s Disease. J Rheumatol (1992) 19(3):424–30.

6. Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease. Med (Baltimore) (2002) 81(3):194–200. doi: 10.1097/00005792-200205000-00003

7. Fautrel B. Ferritin Levels in Adult Still’s Disease: Any Sugar? Joint Bone Spine (2002) 69(4):355–7. doi: 10.1016/s1297-319x(02)00409-8

8. Girard C, Rech J, Brown M, Allali D, Roux-Lombard P, Spertini F, et al. Elevated Serum Levels of Free Interleukin-18 in Adult-Onset Still’s Disease. Rheumatol (Oxford) (2016) 55(12):2237–47. doi: 10.1093/rheumatology/kew300

9. Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P. Adult Onset Still’s Disease (AOSD) in the Era of Biologic Therapies: Dichotomous View for Cytokine and Clinical Expressions. Autoimmun Rev (2014) 13 (11):1149–59. doi: 10.1016/j.autrev.2014.08.032

10. Colafrancesco S, Priori R, Alessandri C, Perricone C, Pendolino M, Picarelli G, et al. IL-18 Serum Level in Adult Onset Still’s Disease: A Marker of Disease Activity. Int J Inflamm (2012) 2012:156890. doi: 10.1155/2012/156890

11. Nam SW, Kang S, Lee JH, Yoo DH. Different Features of Interleukin-37 and Interleukin-18 as Disease Activity Markers of Adult-Onset Still’s Disease. J Clin Med (2021) 10(5):910. doi: 10.3390/jcm10050910

12. Jung KH, Kim JJ, Lee JS, Park W, Kim TH, Jun JB, et al. Interleukin-18 as an Efficient Marker for Remission and Follow-Up in Patients With Inactive Adult-Onset Still’s Disease. Scand J Rheumatol (2014) 43(2):162–9. doi: 10.3109/03009742.2013.824023

13. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, et al. Open-Label, Multicentre, Dose-Escalating Phase II Clinical Trial on the Safety and Efficacy of Tadekinig Alfa (IL-18BP) in Adult-Onset Still’s Disease. Ann Rheumatic Dis (2018) 77:840–7. doi: 10.1136/annrheumdis-2017-212608

14. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult Haemophagocytic Syndrome. Lancet (2014) 383(9927):1503–16. doi: 10.1016/s0140-6736(13)61048-x

15. La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the Management of Hemophagocytic Lymphohistiocytosis in Adults. Blood (2019) 133(23):2465–77. doi: 10.1182/ blood.2018894618

16. Crayne CB, Albeituni S, Nichols KE, Cron RQ. The Immunology of Macrophage Activation Syndrome. Front Immunol (2019) 10:119. doi: 10.3389/fimmu.2019.00119

17. Krei JM, Moller HJ, Larsen JB. The Role of Interleukin-18 in the Diagnosis and Monitoring of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome - a Systematic Review. Clin Exp Immunol (2021) 203 (2):174–82. doi: 10.1111/cei.13543

18. Henter JI, Horne A, AricóM, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and Therapeutic Guidelines for Hemophagocytic Lymphohistiocytosis. Pediatr Blood Cancer (2007) 48(2):124–31. doi: 10.1002/pbc.21039

19. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical Manifestations But Not Cytokine Profiles Differentiate Adult-Onset Still’s Disease and Sepsis. J Rheumatol (2010) 37(11):2369–76. doi: 10.3899/ jrheum.100247

20. Batu ED, Erden A, Seyhoğlu E, Kilic L, Büyükasık Y, Karadag O, et al. Assessment of the HScore for Reactive Haemophagocytic Syndrome in Patients With Rheumatic Diseases. Scand J Rheumatol (2017) 46(1):44–8. doi: 10.3109/03009742.2016.1167951

21. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, et al. Severe Imbalance of IL-18/IL-18BP in Patients With Secondary Hemophagocytic Syndrome. Blood (2005) 106(10):3483–9. doi: 10.1182/blood-2005-05-1980

22. Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of Interleukin-18 and its Binding Inhibitors in the Blood Circulation of Patients With Adult-Onset Still’s Disease. Arthritis Rheum (2001) 44(3):550–60. doi: 10.1002/1529-0131(200103)44:3<550::Aid- anr103>3.0.Co;2-5

23. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory Cytokine Profiles in Sera and Pathological Tissues of Patients With Active Untreated Adult Onset Still’s Disease. J Rheumatol (2004) 31(11):2189–98.

24. Maruyama J, Inokuma S. Cytokine Profiles of Macrophage Activation Syndrome Associated With Rheumatic Diseases. J Rheumatol (2010) 37 (5):967–73. doi: 10.3899/jrheum.090662

25. Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, et al. Involvement of TLR7 MyD88-Dependent Signaling Pathway in the Pathogenesis of Adult- Onset Still’s Disease. Arthritis Res Ther (2013) 15(2):R39. doi: 10.1186/ar4193

26. Saiki O, Uda H, Nishimoto N, Miwa T, Mima T, Ogawara T, et al. Adult Still’s Disease Reflects a Th2 Rather Than a Th1 Cytokine Profile. Clin Immunol (2004) 112(1):120–5. doi: 10.1016/j.clim.2004.03.023

27. Chen DY, Lan JL, Lin FJ, Hsieh TY. Association of Intercellular Adhesion Molecule-1 With Clinical Manifestations and Interleukin-18 in Patients With Active, Untreated Adult-Onset Still’s Disease. Arthritis Rheum (2005) 53 (3):320–7. doi: 10.1002/art.21164

28. Conigliaro P, Priori R, Bombardieri M, Alessandri C, Barone F, Pitzalis C, et al. Lymph Node IL-18 Expression in Adult-Onset Still’s Disease. Ann Rheum Dis (2009) 68(3):442–3. doi: 10.1136/ard.2008.093781

29. Kim HA, An JM, Nam JY, Jeon JY, Suh CH. Serum S100A8/A9, But Not Follistatin-Like Protein 1 and Interleukin 18, may be a Useful Biomarker of Disease Activity in Adult-Onset Still’s Disease. J Rheumatol (2012) 39 (7):1399–406. doi: 10.3899/jrheum.120079

30. Priori R, Colafrancesco S, Alessandri C, Minniti A, Perricone C, Iaiani G, et al. Interleukin 18: A Biomarker for Differential Diagnosis Between Adult-Onset Still’s Disease and Sepsis. J Rheumatol (2014) 41(6):1118–23. doi: 10.3899/ jrheum.130575

31. Koga T, Sumiyoshi R, Furukawa K, Sato S, Migita K, Shimizu T, et al. Interleukin-18 and Fibroblast Growth Factor 2 in Combination Is a Useful Diagnostic Biomarker to Distinguish Adult-Onset Still’s Disease From Sepsis. Arthritis Res Ther (2020) 22(1):108. doi: 10.1186/s13075-020-02200-4

32. Chen PK, Lan JL, Li JP, Chang CK, Chang SH, Huang PH, et al. Elevated Plasma Galectin-3 Levels and Their Correlation With Disease Activity in Adult-Onset Still’s Disease. Clin Rheumatol (2020) 39(6):1945–52. doi: 10.1007/s10067-020-04946-3

33. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The Hyperferritinemic Syndrome: Macrophage Activation Syndrome, Still’s Disease, Septic Shock and Catastrophic Antiphospholipid Syndrome. BMC Med (2013) 11:185. doi: 10.1186/1741-7015-11-185

34. Chen PK, Lan J-L, Huang P-H, Hsu J-L, Chang C-K, Tien N, et al. Interleukin-18 Is a Potential Biomarker to Discriminate Active Adult-Onset Still’s Disease From COVID-19. Front Immunol (2021) 12:719544. doi: 10.3389/fimmu.2021.719544

35. Weiss ES, Girard-Guyonvarc’h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 Diagnostically Distinguishes and Pathogenically Promotes Human and Murine Macrophage Activation Syndrome. Blood (2018) 131(13):1442–55. doi: 10.1182/blood-2017-12-820852

36. Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, et al. Interleukin-18 for Predicting the Development of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Clin Immunol (2015) 160 (2):277–81. doi: 10.1016/j.clim.2015.06.005

37. Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank M, et al. Scd163 in AOSD: A Biomarker for Macrophage Activation Related to Hyperferritinemia. Immunol Res (2014) 60(2-3):177–83. doi: 10.1007/ s12026-014-8563-7

38. Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum Cytokine Profiles in Patients With Adult Onset Still’s Disease. J Rheumatol (2003) 30(11):2422–7.

39. Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M, et al. Clinical Utility of Soluble Interleukin-2 Receptor in Hemophagocytic Syndromes: A Systematic Scoping Review. Ann Hematol (2017) 96(8):1241–51. doi: 10.1007/ s00277-017-2993-y

40. Coca A, Bundy KW, Marston B, Huggins J, Looney RJ. Macrophage Activation Syndrome: Serological Markers and Treatment With Anti-Thymocyte Globulin. Clin Immunol (2009) 132(1):10–8. doi: 10.1016/j.clim.2009.02.005

41. Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A High sIL-2R/Ferritin Ratio is a Useful Marker for the Diagnosis of Lymphoma-Associated Hemophagocytic Syndrome. Ann Hematol (2014) 93(5):821–6. doi: 10.1007/ s00277-013-1925-8

42. Hayden A, Lin M, Park S, Pudek M, Schneider M, Jordan MB, et al. Soluble Interleukin-2 Receptor is a Sensitive Diagnostic Test in Adult HLH. Blood Adv (2017) 1(26):2529–34. doi: 10.1182/bloodadvances. 2017012310

43. Naymagon L, Tremblay D, Troy K, Mascarenhas J. Soluble Interleukin-2 Receptor (sIL-2r) Level Is a Limited Test for the Diagnosis of Adult Secondary Hemophagocytic Lymphohistiocytosis. Eur J Haematol (2020) 105(3):255–61. doi: 10.1111/ejh.13433

44. Fautrel B. Adult-Onset Still Disease. Best Pract Res Clin Rheumatol (2008) 22 (5):773–92. doi: 10.1016/j.berh.2008.08.006

45. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct Cytokine Profiles of Systemic-Onset Juvenile Idiopathic Arthritis- Associated Macrophage Activation Syndrome With Particular Emphasis on the Role of Interleukin-18 in its Pathogenesis. Rheumatol (Oxford) (2010) 49 (9):1645–53. doi: 10.1093/rheumatology/keq133

46. Kasama T, Furuya H, Yanai R, Ohtsuka K, Takahashi R, Yajima N, et al. Correlation of Serum CX3CL1 Level With Disease Activity in Adult- Onset Still’s Disease and Significant Involvement in Hemophagocytic Syndrome. Clin Rheumatol (2012) 31(5):853–60. doi: 10.1007/s10067- 012-1952-1

47. Kaplanski G. Interleukin-18: Biological Properties and Role in Disease Pathogenesis. Immunol Rev (2018) 281(1):138–53. doi: 10.1111/ imr.12616

48. Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive Hemophagocytic Syndrome in Adult Systemic Disease: Report of Twenty-Six Cases and Literature Review. Arthritis Rheum (2003) 49(5):633–9. doi: 10.1002/art.11368

49. Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, et al. Macrophage Activation Syndrome in Still’s Disease: Analysis of Clinical Characteristics and Survival in Paediatric and Adult Patients. Clin Rheumatol (2017) 36(12):2839–45. doi: 10.1007/s10067-017-3830-3

50. Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, et al. Prognostic Factors of Macrophage Activation Syndrome, at the Time of Diagnosis, in Adult Patients Affected by Autoimmune Disease: Analysis of 41 Cases Collected in 2 Rheumatologic Centers. Autoimmun Rev (2017) 16 (1):16–21. doi: 10.1016/j.autrev.2016.09.016

51. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome. Arthritis Rheumatol (2014) 66(9):2613–20. doi: 10.1002/art.38690

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る